Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "50" vs ALDORIL D30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hypertension
Hypertension
Hydrochlorothiazide 50 mg orally once daily.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Hydrochlorothiazide is not extensively metabolized. Reserpine is metabolized primarily in the liver by CYP450 enzymes.
Methyldopa is metabolized by conjugation (catechol-O-methyltransferase) and hepatic sulfation; hydrochlorothiazide is not extensively metabolized and is excreted unchanged by the kidney.
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
90-96% (primarily to albumin and alpha1-acid glycoprotein)
Methyldopa: <10% bound to plasma proteins; hydrochlorothiazide: 40-68% bound to albumin.
200-400 L/kg (extremely large due to extensive tissue binding, especially in adrenergic nerve terminals)
Methyldopa: Vd 0.2-0.3 L/kg (distributes into tissues, crosses placenta); hydrochlorothiazide: Vd 0.75-1.5 L/kg (extensively distributed, does not cross blood-brain barrier significantly).
Oral: 40-50% (extensive first-pass metabolism)
Oral bioavailability of methyldopa is approximately 25% (variable, influenced by gut metabolism); hydrochlorothiazide bioavailability is 65-75%.
Contraindicated in anuria. For GFR 30-60 m L/min: reduce dose to 25 mg daily. For GFR <30 m L/min: not recommended.
GFR 30-60 m L/min: reduce dose by 50%; GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B/C: use with caution; monitor electrolytes and renal function; reduce dose if needed.
Child-Pugh Class B or C: contraindicated; use not recommended.
Not typically recommended; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Initiate at 12.5-25 mg orally once daily; titrate cautiously; monitor electrolytes and renal function.
Start with lowest dose; monitor for hypotension, electrolyte imbalance, and CNS effects; consider reduced initial dose.
None
None
Electrolyte imbalance (especially hypokalemia),Sulfonamide allergy (hydrochlorothiazide),Mental depression (reserpine),Bradycardia and arrhythmias (reserpine)
May cause hemolytic anemia, liver disorders, positive Coombs test, sedation, depression, and hypersensitivity reactions. Hydrochlorothiazide may cause electrolyte imbalance, hyperuricemia, photosensitivity, and exacerbation of systemic lupus erythematosus. Use with caution in renal impairment, hepatic disease, and in patients with a history of drug-induced hemolytic anemia.
Anuria,Known sulfonamide allergy (hydrochlorothiazide),History of mental depression (reserpine),Active peptic ulcer or ulcerative colitis (reserpine),Electroconvulsive therapy (reserpine)
Active hepatic disease, history of previous methyldopa therapy-associated liver disorders; anuria; hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamide-derived drugs.
Avoid high-sodium foods (e.g., processed meats, canned soups) to prevent fluid retention and counteract antihypertensive effects. Avoid excessive potassium-rich foods (e.g., bananas, oranges, spinach) as thiazides cause potassium loss; however, reserpine may not affect potassium levels. Limit alcohol intake. Take with food or milk to reduce gastrointestinal upset.
Food may decrease absorption of methyldopa. Avoid excessive intake of high-potassium foods (e.g., bananas, oranges) unless directed. Hydrochlorothiazide may cause potassium depletion; maintain adequate dietary potassium. Avoid natural licorice as it can worsen hypokalemia.
Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association with congenital anomalies not established. Second and third trimesters: May cause fetal or neonatal electrolyte disturbances, hypoglycemia, and decreased placental perfusion. Reserpine: First trimester: Animal studies show no teratogenic effects, human data insufficient. Second and third trimesters: May cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to depletion of catecholamines.
First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; possible fetal bradycardia and neonatal hypotension. Hydrochlorothiazide may cause fetal/neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Hydrochlorothiazide: Excreted into human milk in small amounts; M/P ratio approximately 0.2. Reserpine: Excreted into breast milk; M/P ratio not well established. Both are considered compatible with breastfeeding by most authorities, but use caution as reserpine may cause gastrointestinal disturbances, nasal congestion, and lethargy in the infant. Monitor infant for side effects.
Methyldopa is excreted in breast milk in low concentrations; M/P ratio approximately 0.2. Hydrochlorothiazide is excreted in minimal amounts; may suppress lactation. Consider risks versus benefits.
Hydrochlorothiazide: Dose adjustment not typically required for pharmacokinetic changes, but use lowest effective dose due to risk of decreased placental perfusion. Reserpine: No specific dose adjustment recommended for pregnancy. Monitor for hypotension and avoid use near term to reduce neonatal adverse effects.
Methyldopa: Pregnancy-induced plasma volume expansion may require dose titration; monitor blood pressure and adjust accordingly. Hydrochlorothiazide: Often avoided in pregnancy due to volume depletion risks; if used, monitor electrolytes and renal function, no pharmacokinetic data necessitate routine dose adjustment.
Hydrochlorothiazide 50 mg plus reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause depression; avoid in patients with history of depression. Onset of antihypertensive effect is 3-6 hours. Use with caution in patients with renal impairment (Cr Cl <30 m L/min) as thiazides are ineffective.
ALDORIL D30 combines methyldopa (central alpha-2 agonist) and hydrochlorothiazide (thiazide diuretic). Monitor for orthostatic hypotension, especially at initiation. Taper not needed for methyldopa but discontinue if fever or liver dysfunction occurs. Interferes with urinary catecholamine measurements (false elevation). Hydrochlorothiazide may cause hyponatremia, hypokalemia, and hyperglycemia; check electrolytes and glucose periodically.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug may make you dizzy; avoid driving or operating machinery until you know how it affects you.,Reserpine can cause nasal congestion, drowsiness, or depression; contact your doctor if you experience mood changes.,Avoid alcohol as it may increase dizziness and drowsiness.,Stay hydrated but do not overhydrate; report excessive thirst, dry mouth, or muscle cramps.,Do not stop taking this medication abruptly as it may cause a rapid increase in blood pressure.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,This medication may increase your sensitivity to sunlight; use sunscreen and protective clothing.
Take exactly as prescribed, preferably with food to reduce stomach upset.,Rise slowly from sitting or lying down to prevent dizziness.,This drug may make you drowsy; avoid driving or operating machinery until you know how it affects you.,Report fever, unexplained fatigue, jaundice, or dark urine immediately.,Weigh yourself daily and report rapid weight gain or swelling.,Limit alcohol intake as it can increase side effects.,Do not use salt substitutes containing potassium without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "50" vs ALDORIL D30, answered by our medical review team.
HYDRO-SERP "50" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.. ALDORIL D30 is a Antihypertensive Combination that works by Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "50" and ALDORIL D30 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "50" is: Hydrochlorothiazide 50 mg orally once daily.. The standard adult dose of ALDORIL D30 is: Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "50" and ALDORIL D30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "50" is classified as Category C. Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association wi. ALDORIL D30 is classified as Category C. First trimester: Limited data; no clear evidence of major malformations but methyldopa crosses placenta. Second and third trimesters: Associated with reduced placental perfusion; p. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.